Clinical trial Recruiting at 1 site Observational Ages 18 and up

Red Cell Distribution Width to Albumin Ratio in Burn Patients

Official title: Measurement of Red Cell Distribution Width/Albumin Ratio as a Predictive Tool for 30-day Mortality of Patients With Burn Injuries

Run by Ain Shams University · NCT07761845 · Data updated 2026-11-12

This observational study tests whether the ratio of red cell distribution width to albumin measured within 24 hours of admission can predict 30-day mortality in adults with burn injuries.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment30 (estimated)
SponsorAin Shams University
Academic / other
Drugs / interventionschemotherapy
Locations1 site (Cairo, Cairo Governorate)
StatusRecruiting
StartedAugust 1, 2026
Main results expectedFebruary 1, 2027
Study endsApril 1, 2027
Registry record updatedAugust 18, 2026
Trial IDNCT07761845 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults over 18 with burn injuries covering more than 20% TBSA, admitted to ICU within 24 hours, and with complete admission labs (RDW and albumin).

Probably not a fit

Patients without complete admission labs or with burns under 20% TBSA may not benefit from the findings.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study collects data from adults with burn injuries to see if the RDW/albumin ratio measured within 24 hours of hospital arrival can predict 30-day mortality. It records patient characteristics, burn severity, and comorbidities, and follows standard burn resuscitation practices in the first 72 hours, including fluid management and monitoring. No specific intervention is tested beyond routine care and the prognostic value of the biomarker ratio. The study uses ICU patients admitted within 24 hours and relies on laboratory data obtained on admission to calculate the ratio and assess its association with 30-day outcomes.

Why it matters

Potential benefit: If the RDW/albumin ratio proves predictive, clinicians may better identify high-risk burn patients early and tailor monitoring and resources accordingly.

How similar studies have gone: Observational studies in critical illness have explored RDW and albumin as prognostic markers, but the specific RDW/albumin ratio in burn mortality prediction is less established and requires validation.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age \> 18 years.
* Both sexes.
* Patients with burn injuries (%TBSA \>20%).
* Availability of complete laboratory data (RDW, albumin) on admission.
* Admission to ICU within 24 hours of burn injury.

Exclusion Criteria:

* Age \<18 years.
* Patients with chronic hematologic disease.
* Pre-existing liver disease.
* Nephrotic syndrome.
* patients on chemotherapy.
* Patients with incomplete or missing lab records.
* Pregnant females.
* Patient or guardian refusal.

Where it's running

  • Ain shams university
    Cairo, Cairo Governorate, Egypt
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.